风险缓解指导阿片类药物与兴奋剂配药对双重公共卫生紧急事件期间死亡率和急性医疗就诊的影响:回顾性队列研究
该研究基于加拿大不列颠哥伦比亚省人群的回顾性队列,纳入 5882 名阿片类药物或兴奋剂使用障碍者,其中 5356 人接受阿片类风险缓解指导(RMG)处方、1061 人接受兴奋剂 RMG 处方(535 人两者均接受),时间范围为 2020 年 3 月 27 日至 2021 年 8 月 31 日。通过高维倾向评分 1:1 匹配对照,并采用周时间步长的边际结构模型分析配药后一周内的结局。结果显示,阿片类 RMG 配药≥1 天与全因死亡率降低(调整 HR 0.39,95%CI 0.25–0.60)和过量相关死亡率降低(0.45,0.27–0.75)相关;兴奋剂 RMG 配药≥1 天与全因死亡率(0.50,0.20–1.23)和过量相关死亡率(0.53,0.18–1.56)无显著关联。阿片类 RMG 配药未显著改变全因或过量相关急性医疗就诊的比值;兴奋剂 RMG 配药与任何原因急性医疗就诊比值显著降低相关,但未影响过量相关急性医疗就诊比值。作者认为,药物替代非法药物供应是降低阿片类药物使用障碍者死亡率的有前景的干预措施。
要点
- 阿片类 RMG 配药≥1 天与随后一周全因死亡率降低相关(调整 HR 0.39,95%CI 0.25–0.60)和过量相关死亡率降低相关(0.45,0.27–0.75)。
- 阿片类 RMG 配药的保护效应随每周配药天数增加而增强:配药≥4 天者全因死亡率调整 HR 0.09(0.04–0.21),过量相关死亡率 0.11(0.04–0.32)。
- 兴奋剂 RMG 配药≥1 天与全因死亡率(调整 HR 0.50,95%CI 0.20–1.23)和过量相关死亡率(0.53,0.18–1.56)无显著关联。
- 阿片类 RMG 配药未显著改变全因或过量相关急性医疗就诊的比值;兴奋剂 RMG 配药与任何原因急性医疗就诊比值显著降低相关,但未影响过量相关急性医疗就诊比值。
- 作者认为,药物替代非法药物供应是降低阿片类药物使用障碍者死亡率的有前景的干预措施。
适用人群与场景
- 加拿大不列颠哥伦比亚省 5882 名阿片类药物或兴奋剂使用障碍者,2020 年 3 月 27 日至 2021 年 8 月 31 日期间接受 RMG 处方:阿片类 n=5356,兴奋剂 n=1061,两者均接受 n=535。
研究设计与关键结果
- 研究设计:基于人群的回顾性队列研究,采用高维倾向评分 1:1 匹配对照,并以周时间步长的边际结构模型分析 RMG 配药后一周内的结局。
- 阿片类 RMG 配药≥1 天与全因死亡率降低相关(调整 HR 0.39,95%CI 0.25–0.60),与过量相关死亡率降低相关(0.45,0.27–0.75)。
- 阿片类 RMG 配药≥4 天者较对照组全因死亡率降低(调整 HR 0.09,95%CI 0.04–0.21),过量相关死亡率降低(0.11,0.04–0.32)。
- 兴奋剂 RMG 配药≥1 天与全因死亡率无显著关联(调整 HR 0.50,95%CI 0.20–1.23),与过量相关死亡率无显著关联(0.53,0.18–1.56)。
- 阿片类 RMG 配药未显著改变全因或过量相关急性医疗就诊的比值。
- 兴奋剂 RMG 配药与任何原因急性医疗就诊比值显著降低相关,但未影响过量相关急性医疗就诊比值。
证据类型、等级与局限
- 证据类型:基于人群的回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,药物替代非法药物供应是降低阿片类药物使用障碍者死亡率的有前景的干预措施。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine the effect of opioid and stimulant Risk Mitigation Guidance (RMG) dispensations on mortality and acute care visits during the dual public health emergencies of overdose and covid-19.
DESIGN: Population based retrospective cohort study.
SETTING: British Columbia, Canada.
PARTICIPANTS: 5882 people with opioid or stimulant use disorder who received RMG prescriptions for opioids (n=5356) and/or stimulants (n=1061) (535 received both) from 27 March 2020 to 31 August 2021.
MAIN OUTCOME MEASURES: All cause and overdose specific mortality and acute care visits in the week after RMG opioid or stimulant dispensation. RMG recipients were matched 1:1 with controls through use of high dimensional propensity score matching. Marginal structural models, executed on weekly time steps, were used to measure the effect of dispensations on outcomes.
RESULTS: RMG opioid dispensations of one day or more were associated with reduced all cause mortality (adjusted hazard ratio 0.39, 95% confidence interval 0.25 to 0.60) and overdose related mortality (0.45, 0.27 to 0.75) in the subsequent week. Dispensations of RMG stimulants (≥1 days) were not significantly associated with reduced all cause mortality (adjusted hazard ratio 0.50, 0.20 to 1.23) or overdose related mortality (0.53, 0.18 to 1.56). The protective effect of RMG opioid dispensations increased with the number of days the medications were dispensed in a given week. People who received four or more days of RMG opioid dispensations had reduced all cause mortality (adjusted hazard ratio 0.09, 0.04 to 0.21) and overdose related mortality (0.11, 0.04 to 0.32) compared with the control group. Opioid RMG dispensations did not significantly modify the odds of all cause or overdose related acute care visits. Dispensations of RMG stimulants were associated with a significant decrease in the odds of acute care visits for any cause but did not affect the odds of overdose related acute care visits.
CONCLUSIONS: RMG opioid dispensations were associated with reduced overdose related and all cause mortality among a sample of people with opioid use disorder. Pharmaceutical alternatives to the illegal drug supply are promising interventions to reduce mortality in people with opioid use disorder.
参考来源
- Slaunwhite A, Min JE, Palis H, et al. Effect of Risk Mitigation Guidance opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: retrospective cohort study. BMJ. 2024. PMID: 38199614. doi:10.1136/bmj-2023-076336
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。